StockData

ProPhase Labs, Inc. (PRPH) stock

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30
$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

ProPhase Labs operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ProPhase Labs's operating income for the twelve months ending Jun 30, 2026 was -$15.56M. For fiscal 2025 it was -$18.05M. The highest annual figure on record is $23.60M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.05M–
FY2024Dec 31, 2024-$38.63M–
FY2023Dec 31, 2023-$21.22M-189.9%
FY2022Dec 31, 2022$23.60M+140.7%
FY2021Dec 31, 2021$9.80M–
FY2020Dec 31, 2020-$2.08M–
FY2019Dec 31, 2019-$3.24M–
FY2018Dec 31, 2018-$1.63M–
FY2017Dec 31, 2017-$3.99M–
FY2016Dec 31, 2016-$2.66M–
FY2015Dec 31, 2015-$3.58M–
FY2014Dec 31, 2014-$7.83M-1981.7%
FY2013Dec 31, 2013$416.00K–
FY2012Dec 31, 2012-$1.10M–
FY2011Dec 31, 2011-$2.74M–
FY2010Dec 31, 2010-$3.59M–
FY2009Dec 31, 2009-$3.94M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.65M–
Q1 FY2026Mar 31, 2026-$2.43M–
Q4 FY2025Dec 31, 2025-$5.73M–
Q3 FY2025Sep 30, 2025-$4.76M–
Q2 FY2025Jun 30, 2025-$3.89M–
Q1 FY2025Mar 31, 2025-$3.66M–
Q4 FY2024Dec 31, 2024-$17.29M–
Q3 FY2024Sep 30, 2024-$6.48M–
Q2 FY2024Jun 30, 2024-$7.23M–
Q1 FY2024Mar 31, 2024-$7.63M-972.1%
Q4 FY2023Dec 31, 2023-$10.96M–
Q3 FY2023Sep 30, 2023-$6.48M-431.7%
Q2 FY2023Jun 30, 2023-$4.66M-144.0%
Q1 FY2023Mar 31, 2023$875.00K-94.6%
Q4 FY2022Dec 31, 2022-$5.09M-137.2%
Q3 FY2022Sep 30, 2022$1.95M–
Q2 FY2022Jun 30, 2022$10.59M–
Q1 FY2022Mar 31, 2022$16.15M+1222.4%
Q4 FY2021Dec 31, 2021$13.68M–
Q3 FY2021Sep 30, 2021-$3.65M–
Q2 FY2021Jun 30, 2021-$1.45M-2557.6%
Q1 FY2021Mar 31, 2021$1.22M–
Q4 FY2020Dec 31, 2020-$761.00K–
Q3 FY2020Sep 30, 2020-$567.00K–
Q2 FY2020Jun 30, 2020$59.00K–
Q1 FY2020Mar 31, 2020-$812.00K–
Q4 FY2019Dec 31, 2019-$466.00K–
Q3 FY2019Sep 30, 2019-$461.00K–
Q2 FY2019Jun 30, 2019-$1.27M–
Q1 FY2019Mar 31, 2019-$1.04M–
Q4 FY2018Dec 31, 2018-$406.00K–
Q3 FY2018Sep 30, 2018-$912.00K–
Q2 FY2018Jun 30, 2018-$264.00K–
Q1 FY2018Mar 31, 2018-$53.00K–
Q4 FY2017Dec 31, 2017-$332.00K-143.6%
Q3 FY2017Sep 30, 2017-$902.00K–
Q2 FY2017Jun 30, 2017-$886.00K–
Q1 FY2017Mar 31, 2017-$745.00K–
Q4 FY2016Dec 31, 2016$761.00K–
Q3 FY2016Sep 30, 2016-$786.00K–

More ProPhase Labs figures

See a number that looks wrong?